News archive

Copenhagen Capacity and BioInnovation Institute is welcoming OvartiX, a company conducting a large-scale study to investigate how genetic testing can predict the onset of menopause, to Copenhagen. OvartiX aims to develop new treatments for female reproductive health using a unique drug discovery platform that combines large-scale data, human cellular engineering, and animal models. Their goal is to create advanced therapies to address fertility and ovarian function, offering new solutions for women facing reproductive health challenges.

The company identified Copenhagen as an optimal location for their research. The decision to bring OvartiX to Copenhagen was influenced by guidance provided by Copenhagen Capacity.

OvartiX is positively impressed about the essential resources, networks, and local infrastructure that Medicon Valley has to offer for a company within Women’s health.  Their understanding of the local business environment and life sciences sector made Copenhagen the ideal choice.

"We are excited to welcome OvartiX to Copenhagen. Their large-scale study on predicting menopause onset and their innovative approach to female reproductive health will be a valuable addition to our life sciences ecosystem, supporting Denmark’s health goals " – Asbjørn Overgaard, CEO at Copenhagen Capacity.

Copenhagen’s growing reputation as a hub for life sciences and healthcare innovation was a key factor in OvartiX’s decision. The city offers a strategic advantage with its world-class research institutions, access to top talent, and collaborative atmosphere. The presence of BioInnovation Institute, which provides funding, business development support, and access to a global network, was the convincing factor. This partnership between Copenhagen Capacity, BioInnovation Institute, and OvartiX highlights the city’s role in driving innovation in female-specific health research and reinforces its position as a leading destination for healthcare companies.